FindTrial
Sign In

veledimex

DRUG6 trials

Sponsors

Alaunos Therapeutics, Castle Creek Biosciences, LLC.

Conditions

Anaplastic OligoastrocytomaGlioblastomaGlioblastoma MultiformeMetastatic Breast CancerMorpheaSclerodermaScleroderma, Localized

Phase 1

A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
CompletedNCT02026271
Alaunos TherapeuticsAnaplastic Oligoastrocytoma, Glioblastoma Multiforme
Start: 2015-06-30End: 2019-08-31Updated: 2025-04-16
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
TerminatedNCT02423902
Alaunos TherapeuticsMetastatic Breast Cancer
Start: 2015-07-18End: 2016-07-19Updated: 2025-08-28
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
CompletedNCT03636477
Alaunos TherapeuticsGlioblastoma
Start: 2018-06-18End: 2021-06-30Updated: 2025-08-12
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
CompletedNCT03679754
Alaunos TherapeuticsGlioblastoma
Start: 2018-09-05End: 2021-01-19Updated: 2025-08-28
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
TerminatedNCT03740724
Castle Creek Biosciences, LLC.Morphea, Scleroderma, Scleroderma, Localized
Start: 2019-12-18End: 2022-04-21Updated: 2024-01-23

Phase 2

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
TerminatedNCT04006119
Alaunos TherapeuticsGlioblastoma
Start: 2019-08-01End: 2021-08-05Updated: 2025-04-18

Related Papers

Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial
Neuro-Oncology2021-11-23101 citations
CTIM-20. FINAL RESULTS OF CONTROLLED IL-12 MONOTHERAPY AND IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology2021-11-024 citations
CTIM-28. PHASE 2 TRIAL OF CONTROLLED IL-12 IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (rGBM)
Neuro-Oncology2020-11-01
CTIM-05. COMBINATION OF CONTROLLED INTERLEUKIN-12 GENE THERAPY WITH IMMUNE CHECKPOINT BLOCKADE IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS OF A MULTI-INSTITUTIONAL, OPEN LABEL PHASE 1 TRIAL
Neuro-Oncology2020-11-01
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.
Journal of Clinical Oncology2020-05-203 citations
Final results of controlled IL-12 monotherapy in adults with grade III or IV gliomas.
Journal of Clinical Oncology2020-05-202 citations
Survival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone.
Journal of Clinical Oncology2020-05-201 citations
ATIM-25. PD-1 INHIBITION CAN BE COMBINED WITH IL-12 IN SUBJECTS WITH RECURRENT GLIOBLASTOMA
Neuro-Oncology2019-11-01
ATIM-18. SURVIVAL OF SUBJECTS WITH RECURRENT GLIOBLASTOMA RECEIVING INTRA-TUMORAL ADMINISTRATION OF IL-12 MANAGED WITH LOW-DOSE DEXAMETHASONE
Neuro-Oncology2019-11-01
Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.
2019-08-01209 citations
Evaluation of controlled IL-12 in combination with a PD-1 inhibitor in subjects with recurrent glioblastoma.
Journal of Clinical Oncology2019-05-204 citations
Evaluation of controlled IL-12 as monotherapy in subjects with recurrent GBM.
Journal of Clinical Oncology2019-05-20
Demonstration of anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in advanced breast cancer and recurrent glioblastoma patients.
Journal of Clinical Oncology2018-05-203 citations
Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: Tolerability and survival in recurrent glioblastoma.
Journal of Clinical Oncology2017-05-208 citations
P06.09 In vitro assessment of human IL-12Fc function on porcine and canine peripheral blood mononuclear cells
Neuro-Oncology2017-04-01
Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.
Journal of Clinical Oncology2016-05-207 citations
Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer.
Journal of Clinical Oncology2016-05-20
Abstract OT1-01-05: Phase 1b/2 study of intratumoral Ad-RTS-hIL-12 + veledimex in patients with chemotherapy-responsive locally advanced or metastatic breast cancer
Cancer Research2016-02-15